Pharmacokinetics of Generic Pediatric Abacavir/Lamivudine Dispersible Tablets in Thai Young Children Living With HIV Weighing Below Twenty Kilograms

We investigated the steady-state pharmacokinetics of generic abacavir (ABC)/lamivudine (3TC) dispersible tablets (DTs) in young children living with HIV aged 3 months to <7 years, weighing 6 to <20 kg. Twenty-eight Thai children were enrolled and received ABC/3TC-DT plus pediatric dolutegravir-DT once daily. ABC/3TC was administered using WHO weight band (WB) doses: 180/90 mg, 240/120 mg and 300/150 mg for children weighing 6 to <10 kg (WB 1, n = 7), 10 to <14 kg (WB2, n = 9) and 14 to <20 kg (WB3, n = 12), respectively. ABC geometric mean (GM) AUC_{0–24 h} (CV%) was 14.2 (50.5%), 15.6 (32.6%) and 20.7 (28.3%) mg.h/L, respectively, and 3TC GM AUC_{0–24 h} was 14.8 (44.1%), 18.2 (28.0%) and 19.9 (26.2%) mg.h/L, respectively. ABC and 3TC exposures were within target ranges across WBs. These data supported current ABC/3TC-DT WHO-weight band dosing guidance for young children in Thailand.